Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — The federal government on Thursday finalized a rule that requires health insurers to publicly disclose the rates they negotiate with hospitals, doctors, and drug manufacturers.

The move represents a dramatic change to the health care marketplace, and likely will result in significant added transparency between competing industry groups and, to an extent, for patients. It will significantly impact the pharmaceutical industry in particular: It requires private-sector insurers to disclose drug prices either negotiated directly with drug manufacturers or through pharmacy benefit managers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • My Medicare Advantage plan sends me a quarterly summary of out of pocket spending for medical and hospital claims. It also tells me how much counts toward my out of pocket maximum. I get similar reports on drug spending.

Comments are closed.